Cargando…
Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis
Glucocorticoid-induced osteoporosis (GIOP) is a serious problem for patients with rheumatic diseases requiring long-term glucocorticoid treatment. Alendronate, a bisphosphonate, has been recommended in the prevention of GIOP. However, the efficacy and safety of alendronate in preventing GIOP remains...
Autores principales: | Kan, Shun-Li, Yuan, Zhi-Fang, Li, Yan, Ai, Jie, Xu, Hong, Sun, Jing-Cheng, Feng, Shi-Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998340/ https://www.ncbi.nlm.nih.gov/pubmed/27336902 http://dx.doi.org/10.1097/MD.0000000000003990 |
Ejemplares similares
-
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis
por: Liu, Qingshan, et al.
Publicado: (2020) -
The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
por: Li, Wan, et al.
Publicado: (2015) -
Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis
por: Franco, André Silva, et al.
Publicado: (2017) -
Pharmacological and non-pharmacological interventions for osteoporosis: A protocol for an overview with an evidence map and a network meta-analysis of trials
por: Tian, Jidong, et al.
Publicado: (2021) -
Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis
por: Yu, Kuang-Hui, et al.
Publicado: (2022)